<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fabry disease: Treatment and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fabry disease: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fabry disease: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Mauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Wallace, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raphael Schiffmann, MD, MHSc, FAAN</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary C Curhan, MD, ScD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H367029353"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fabry disease, also called Anderson-Fabry disease, is the second most prevalent lysosomal disease after Gaucher disease. It is an X-linked inborn error of the glycosphingolipid metabolic pathway. This results in accumulation of globotriaosylceramide (Gb3) primarily within lysosomes in a wide variety of cells, thereby leading to the protean manifestations of the disease.</p><p>There is no cure for Fabry disease. Treatment options include both Fabry-specific and non-Fabry-specific therapies. Available Fabry-specific therapies include recombinant alpha-galactosidase A (alpha-Gal A), the enzyme that is deficient in patients with Fabry disease, and <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> hydrochloride, an oral pharmacologic chaperone that corrects folding of mutated alpha-Gal A in patients with Fabry disease and amenable alpha-Gal A mutations. The impact of these therapies on mortality is unknown. Non-Fabry-specific therapies include adjunctive therapies for complications such as chronic kidney disease (CKD), cardiac disease, neurologic disease, gastrointestinal disease, and other clinical manifestations. </p><p>The treatment and prognosis of Fabry disease are presented here. Other aspects of this disease are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4914.html" rel="external">"Fabry disease: Cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6194.html" rel="external">"Fabry disease: Neurologic manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115165.html" rel="external">"Fabry disease: Kidney manifestations"</a>.)</p><p></p><p class="headingAnchor" id="H3654081248"><span class="h1">PRETREATMENT CONSIDERATIONS</span></p><p class="headingAnchor" id="H1368324951"><span class="h2">Clinical phenotypes</span><span class="headingEndMark"> — </span>Patients with Fabry disease can generally be categorized into the following three clinical phenotypes, which guide the approach to therapy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic Fabry disease </strong>– The classic form of Fabry disease is the most severe clinical phenotype. Males with classic Fabry disease have little or no functional alpha-galactosidase A (alpha-Gal A) enzyme activity (&lt;1 percent of the normal mean). These patients have a childhood or adolescent onset of disease, followed by progressive multiorgan failure and, ultimately, premature death. (See  <a class="medical medical_review" href="/z/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis", section on 'Classic Fabry disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heterozygous females</strong> – Clinical manifestations in heterozygous females with classic mutations can vary widely from no apparent clinical disease to a severe phenotype that resembles that observed in males with classic Fabry disease. This phenotypic variation may be due, at least in part, to skewed (nonrandom) X-chromosome inactivation, which results in a higher percentage of X chromosome with the disease mutation being expressed in affected organs. Heterozygous females may exhibit any or all of the symptoms and signs of Fabry disease. (See  <a class="medical medical_review" href="/z/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis", section on 'Heterozygous females'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with later-onset and cardiac variants </strong>– Males and females with atypical, "later-onset" variants of Fabry disease usually present later in life (fourth to seventh decades of life) than those with the classic form of the disease. They have residual alpha-Gal A activity (between 2 and 30 percent of the normal mean). Many do not display the classical features of Fabry disease, and their disease may sometimes be dominated by a particular organ system, such as the heart or kidney. Patients with cardiac variants have clinical disease limited to the heart. (See  <a class="medical medical_review" href="/z/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis", section on 'Atypical (later-onset) variants'</a>.)</p><p></p><p class="headingAnchor" id="H1982880452"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The overall goals of therapy in patients with Fabry disease are to slow down or prevent progression to irreversible tissue damage, organ failure, and premature death, and to improve quality of life. Treatment generally consists of Fabry-specific therapy (such as enzyme replacement therapy [ERT] or chaperone therapy [<a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a>]) for those with an indication for treatment, as well as adjunctive therapies for complications such as chronic kidney disease (CKD), cardiac disease, neurologic disease, gastrointestinal disease, and other clinical manifestations. (See <a class="local">'Fabry-specific therapy'</a> below and <a class="local">'Supportive care'</a> below.)</p><p>Since the manifestations of Fabry disease vary among individual patients, therapeutic goals should be individualized depending upon the extent of organ involvement. Organ-specific goals include the following [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney </strong>– Fabry disease is associated with progressive CKD and proteinuria that can ultimately progress to end-stage kidney disease (ESKD). Therapeutic goals for Fabry-related kidney disease are to stabilize and prevent the progressive decline in kidney function and to reduce proteinuria to less than 500 mg/day. These goals can be primarily achieved only if therapy is introduced at early stages of CKD. (See  <a class="medical medical_review" href="/z/d/html/115165.html" rel="external">"Fabry disease: Kidney manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac </strong>– Fabry disease is associated with significant cardiac complications, which are the leading cause of death in males and females with Fabry disease [<a href="#rid3">3,4</a>]. Therapeutic cardiac goals include preventing the development or progression of left ventricular hypertrophy, the development of myocardial fibrosis, as well as the development of heart failure [<a href="#rid5">5</a>]. In patients with heart failure symptoms, additional goals include improving exercise tolerance, normal daily activities, and quality of life. Other goals are the prevention of life-threatening arrhythmias including heart block, severe bradyarrhythmias, and malignant ventricular arrhythmias. (See  <a class="medical medical_review" href="/z/d/html/4914.html" rel="external">"Fabry disease: Cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic </strong>– Patients with classic Fabry disease commonly have a small fiber peripheral neuropathy that contributes to neuropathic pain, impaired sweating, and other sensory deficits. In addition, the development of chronic white matter hyperintensities in the central nervous system, likely representing cerebral vasculopathy or arrhythmia-induced ischemic events, contributes to an increased risk of ischemic and hemorrhagic cerebrovascular events [<a href="#rid6">6</a>]. Therapeutic goals include management of acute and chronic neuropathic pain and prevention of ischemic stroke and transient ischemic attacks (TIAs). (See  <a class="medical medical_review" href="/z/d/html/6194.html" rel="external">"Fabry disease: Neurologic manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal </strong>– Gastrointestinal symptoms are common in patients with classic Fabry disease and include abdominal pain, diarrhea, constipation, nausea, and vomiting. In patients who have symptoms of gastrointestinal involvement, the goals of therapy are to reduce these symptoms to improve quality of life. (See  <a class="medical medical_review" href="/z/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis", section on 'Classic Fabry disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other manifestations </strong>– Other clinical manifestations of Fabry disease include dermatologic, ophthalmologic, bone [<a href="#rid7">7</a>], and pulmonary manifestations [<a href="#rid8">8</a>], as well as hearing loss, tinnitus, Raynaud phenomena, lymphedema, and neuropsychiatric complaints. Goals of therapy for these manifestations should focus on management of symptoms with the use of adjunctive therapies. (See <a class="local">'Other clinical manifestations'</a> below.)</p><p></p><p class="headingAnchor" id="H2043167834"><span class="h1">FABRY-SPECIFIC THERAPY</span></p><p class="headingAnchor" id="H2844654334"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Available Fabry-specific therapies include enzyme replacement therapy (ERT) and pharmacologic chaperone therapy (ie, <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> hydrochloride).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ERT </strong>– ERT consists of providing affected patients with the deficient enzyme, alpha-galactosidase A (alpha-Gal A). Three formulations of recombinant human alpha-Gal A are available: <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> (Replagal), <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> (Fabrazyme), and pegunigalsidase alfa-iwxj (Elfabrio). Agalsidase alfa is not approved by the US Food and Drug Administration but is available in other countries. <a class="drug drug_general" data-topicid="141472" href="/z/d/drug information/141472.html" rel="external">Pegunigalsidase alfa</a> is a novel pegylated recombinant alpha-Gal A that was designed to provide a prolonged plasma half-life and potentially reduce the incidence of anti-drug antibodies [<a href="#rid9">9,10</a>]. Agalsidase alfa is generally prescribed at 20 percent of the dose of agalsidase beta. The overall efficacy of the two available agalsidases has not been directly compared in long-term randomized trials [<a href="#rid11">11</a>]. Pegunigalsidase alfa was found to be noninferior to agalsidase beta in slowing the decline of kidney function in a randomized controlled trial [<a href="#rid10">10</a>]. (See <a class="local">'Enzyme replacement therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Migalastat</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">Migalastat</a> is an oral pharmacologic chaperone that binds to and stabilizes specific mutant forms of alpha-galactosidase, thereby facilitating proper trafficking of the enzyme to lysosomes and increasing enzyme activity [<a href="#rid12">12</a>]. Migalastat has been approved in the United States, Canada, and Europe for use as first-line therapy in patients with Fabry disease who have <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgalafoldhcp.com%2Famenability&amp;token=fu2%2BO3uoSQSW8VnaP%2BBn72QlOCVth1Y1NL7%2BunVIqQa9gt%2FpBLyS%2BGZf1f3%2F4lbN&amp;TOPIC_ID=7207" target="_blank">amenable galactosidase alpha (GLA) gene variants</a>. Migalastat should not be used in patients with an estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m<sup>2</sup>. (See <a class="local">'Chaperone therapy (migalastat)'</a> below.)</p><p></p><p>The estimated retail cost of therapy with <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> for one year is approximately USD $300,000 in the United States and Europe. By comparison, the price of <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> is USD $315,000 per year. Insurance coverage for these therapies as well as patient assistance programs is available.</p><p class="headingAnchor" id="H1894001358"><span class="h2">Indications and timing of therapy</span><span class="headingEndMark"> — </span>Although expert guidelines are available [<a href="#rid2">2,13-18</a>], there are no uniform recommendations for the use of Fabry-specific therapy. Clinical practice may vary significantly among different countries. Our recommendations are largely consistent with contemporary guidelines and are guided by the patient's clinical phenotype and genetics. Whenever possible, treatment should be guided by an <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fabrydisease.org%2Findex.php%2Fpds&amp;token=8RYIFfyLhIBYEqeX7m6uPF2p0Ov3C10H7gbT3yTUmnKuSfWeg%2BkpJE1UDxSNiDyc7P0LssnkkUUqEpNnAPcFLA%3D%3D&amp;TOPIC_ID=7207" target="_blank">expert in the management of Fabry disease</a>. (See <a class="local">'Clinical phenotypes'</a> above.)</p><p class="headingAnchor" id="H890241278"><span class="h3">Males with classic Fabry disease</span><span class="headingEndMark"> — </span>For all males with classic Fabry disease (ie, with very low or undetectable levels of alpha-Gal A), we suggest Fabry-specific therapy plus supportive care, rather than supportive care alone. We typically initiate Fabry-specific therapy as soon as possible after the diagnosis is established in adults. In patients who are very young, the timing of initiation of therapy must be weighed against the burdens and possible complications of therapy [<a href="#rid17">17</a>]. The choice of Fabry-specific therapy is discussed below. (See <a class="local">'Choice of therapy'</a> below.)</p><p>Evidence in support of Fabry-specific therapy in males with classic Fabry disease comes from a few randomized, placebo-controlled trials and several observational studies that have examined the efficacy and safety of ERT (<a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> or beta); data for <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> are more limited. Studies in adults have shown that ERT reduces tissue deposition of globotriaosylceramide (Gb3) and may slow the decline of glomerular filtration rate (GFR), reduce left ventricular wall thickness and/or mass, and possibly reduce neuropathic pain [<a href="#rid19">19</a>]. Studies in children have also shown benefits with ERT, including reduction in tissue Gb3 accumulation [<a href="#rid20">20</a>] and potentially reduced pain, improved gastrointestinal symptoms, and increased quality of life [<a href="#rid20">20</a>]. ERT has not been clearly shown in randomized trials to improve patient survival or reduce important clinical endpoints (ie, end-stage kidney disease [ESKD], cardiovascular events, and stroke). However, observational data suggest that the incidence of these clinical endpoints decreases after the first six months of ERT and remains stable thereafter [<a href="#rid21">21,22</a>]. Patients with late manifestations of disease (such as advanced cardiac fibrosis or significant clinical kidney manifestations) at the time of initiation of ERT do not appear to benefit to the same extent as those who initiate ERT at earlier stages of disease [<a href="#rid23">23-28</a>]. Outcomes for different organ systems are summarized below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney outcomes</strong> – The efficacy of ERT on Fabry-related kidney disease in males with classic Fabry disease has been evaluated by several studies, which have collectively reported the following outcomes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Observational studies in adult males have shown that long-term treatment with ERT can result in complete clearance of Gb3 deposits from mesangial and glomerular endothelial cells and can reduce podocyte Gb3 deposits in a dose-dependent manner [<a href="#rid24">24,25</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Short-term clinical trials and long-term observational studies suggest that ERT may slow progressive decline of kidney function and attenuate the early development of albuminuria [<a href="#rid26">26,29-33</a>]. As an example, in a retrospective analysis that compared outcomes of 740 patients who received <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> for a median of five years with those of untreated historical controls, males with a baseline of eGFR &lt;60 mL/min/1.73 m<sup>2</sup> had a mean annualized change in eGFR of -2.9 mL/min/1.73 m<sup>2</sup> compared with -6.8 mL/min/1.73 m<sup>2</sup> in the untreated cohort [<a href="#rid32">32</a>]. Another observational study that followed 151 male patients for 24 months found that early treatment with <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> was associated with a reduced slope of eGFR decline [<a href="#rid26">26</a>]. One randomized trial found comparable rates of GFR loss (expressed as mean annualized eGFR slope decline) over two years with <a class="drug drug_general" data-topicid="141472" href="/z/d/drug information/141472.html" rel="external">pegunigalsidase alfa</a> compared with agalsidase beta [<a href="#rid10">10</a>]. In general, patients with less kidney involvement at the time of initiating ERT appear to benefit more from therapy than those who have more advanced kidney disease [<a href="#rid23">23,26,34,35</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no high-quality evidence showing that ERT reduces the risk of ESKD. Such studies are difficult to perform given the rare nature of the disease, phenotypic variation, and variability in the age of initiation of therapy. In long-term observational studies that followed male patients on ERT for up to 10 years, rates of ESKD have ranged from 7 to 10 percent [<a href="#rid23">23,28,36</a>]. By comparison, in one study, prior to the institution of ERT, ESKD developed in 18 percent of males over a median of 12 years [<a href="#rid37">37</a>]. In another pre-ERT-era study, the incidence of ESKD among males with likely classic Fabry disease exceeded 50 percent by age 50 years and was 100 percent in those surviving to age 60 years [<a href="#rid38">38</a>]. However, assessing the impact of ERT on ESKD based upon these studies is difficult given the changing nature of inclusion criteria and differences in sex, clinical phenotype, and duration of follow-up between the studies. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p class="bulletIndent1">Data for <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> are more limited. In a trial that randomly assigned 50 patients with confirmed amenable <em>GLA </em>variants to oral migalastat or placebo every other day for six months, followed by open-label migalastat for up to an additional 18 months, those treated with migalastat had a greater reduction in Gb3 inclusions per kidney peritubular capillary at six months than those receiving placebo [<a href="#rid39">39</a>]. There were no differences in the change in estimated or measured GFR from baseline to month 6 in either treatment group. Over 24 months, the mean annualized change from baseline in estimated and measured GFR were -0.30 and -1.51 mL/min/1.73 m<sup>2</sup>, respectively. An analysis of paired kidney biopsies of eight males in the trial at baseline and after six months of migalastat found a reduction in podocyte Gb3 inclusions that correlated with a reduction in podocyte foot process width [<a href="#rid40">40</a>]. </p><p></p><p class="bulletIndent1">Observational studies have also reported long-term stability of kidney function for up to nine years of <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> treatment [<a href="#rid41">41,42</a>]. However, the degree to which the specific type of <em>GLA </em>variant, the point in the natural history when treatment was started, sex, and other potential variables impact the stability of kidney function cannot be discerned. No comparative data were presented in these studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac outcomes </strong>– Data from one small randomized, placebo-controlled trial and observational studies have shown that long-term ERT or <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> treatment can reduce left ventricular wall thickness and stabilize or improve left ventricular mass [<a href="#rid27">27,43,44</a>]. However, patients who already have advanced cardiac fibrosis at the time of initiating ERT may not benefit to the same degree [<a href="#rid44">44,45</a>]. The impact of ERT on the risk of cardiovascular events (such as heart failure or myocardial infarction) remains unclear. </p><p></p><p class="bulletIndent1">In the randomized trial comparing <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> with placebo cited above, among patients in both placebo and migalastat groups who received migalastat for up to 18 to 24 months in the open-label extension, there was a significant improvement in left ventricular mass index compared with baseline [<a href="#rid39">39</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic outcomes </strong>– Data are mixed regarding the effect of ERT on neuropathic pain, with some, but not all, studies showing that ERT decreases pain symptoms [<a href="#rid11">11,46</a>]. The effects of ERT on the risk of stroke or transient ischemic attack (TIA) are unclear [<a href="#rid47">47</a>]. In long-term observational studies that followed male patients on ERT for up to 10 years, rates of stroke have ranged from 5 to 10 percent [<a href="#rid23">23,28,36</a>]; by comparison, in one study, prior to the institution of ERT, 11 percent of males developed a stroke over a median of 12 years [<a href="#rid37">37</a>]. Another study found that ERT institution before rather than after severe Fabry-related events was associated with fewer on-ERT strokes [<a href="#rid36">36</a>]. However, assessing the impact of ERT on stroke based upon these studies is limited by the changing nature of how studies in patients with Fabry disease were performed, as well as by differences in clinical phenotype and methods used to reduce stroke risk between the studies.     </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal outcomes </strong>– Data from observational studies suggest that ERT may partially relieve Fabry-associated gastrointestinal symptoms in males [<a href="#rid48">48-52</a>]. As an example, in one study, sustained treatment with <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> was associated with a reduction in the prevalence of self-reported abdominal pain (41 versus 56 percent at baseline) and diarrhea (47 versus 57 percent at baseline) over a median of 4.7 years and 5.5 years, respectively [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">In the randomized trial comparing <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> with placebo cited above, patients in both placebo and migalastat groups who received migalastat for up to 18 to 24 months in the open-label extension experienced a reduction in gastrointestinal symptoms including diarrhea, reflux, and indigestion [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quality of life </strong>– Some [<a href="#rid51">51,53-55</a>], but not all [<a href="#rid56">56,57</a>], studies have shown that ERT may improve quality of life measures among males with classic Fabry disease. </p><p></p><p class="headingAnchor" id="H3282522702"><span class="h3">Female heterozygotes</span><span class="headingEndMark"> — </span>For female heterozygotes who have clinical symptoms or signs of major organ involvement (ie, kidney, cardiac, neurologic, gastrointestinal), we suggest Fabry-specific therapy plus supportive care, rather than supportive care alone. For asymptomatic female heterozygotes with laboratory, histologic, functional, or radiologic evidence of major organ injury, we suggest Fabry-specific therapy plus supportive care, rather than supportive care alone. In asymptomatic females whose baseline evaluation does not reveal evidence of major organ injury, some experts perform a kidney biopsy to determine the extent of histologic involvement and treat with Fabry-specific therapy if substantial Gb3 accumulation is observed. Truly asymptomatic females generally do not receive Fabry-specific therapy but should be monitored every two to three years for the development of new symptoms or signs of Fabry disease. If decisions regarding initiation of Fabry-specific therapy are unclear, testing for skewed X-chromosome inactivation, which has been associated with greater risks for adverse clinical outcomes in females with Fabry disease, can also be considered although this testing is not widely available [<a href="#rid58">58</a>]. The choice of Fabry-specific therapy is discussed below. (See <a class="local">'Choice of therapy'</a> below.)</p><p>Evidence in support of Fabry-specific therapy in symptomatic females with Fabry disease comes primarily from observational studies examining the efficacy and safety of ERT. The randomized trials evaluating ERT enrolled primarily males with classic Fabry disease, and it is uncertain if these results can be broadly extrapolated to females, given their varied phenotypes. Studies in females have shown that ERT reduces plasma and urine Gb3 in those with elevated pretreatment levels and may reduce left ventricular mass and improve quality of life [<a href="#rid59">59</a>]. As with males with Fabry disease, there are no randomized trials showing that ERT improves patient survival or reduces the risk of other important clinical endpoints (ie, ESKD, cardiovascular events, and stroke). However, observational data suggest that the incidence rate of these clinical endpoints decreases after the first six months of ERT and remains stable thereafter [<a href="#rid21">21</a>]. Even more than in males, females with a history of pre-ERT clinical events have been shown to have higher incidence rates of on-ERT clinical events compared with those without pre-ERT events [<a href="#rid36">36</a>]. Outcomes for different organ systems are summarized below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney outcomes </strong>– Data on kidney outcomes in females are provided by a few single-arm clinical trials and multiple observational studies and case reports, which have collectively shown that long-term treatment with ERT may stabilize eGFR but does not appear to have an effect on proteinuria [<a href="#rid26">26,27,31,51,60-62</a>]. ERT also reduces Gb3 deposits within the kidney in females [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">There are no data from randomized trials showing that ERT reduces the risk of ESKD in females, and it appears unlikely that this outcome will be evaluated in future clinical trials in females with Fabry disease [<a href="#rid63">63</a>]. In one long-term observational study that followed 442 females for a median of 3.2 years, 2 percent developed ESKD [<a href="#rid36">36</a>]; by comparison, in a study of 168 females prior to the initiation of ERT, 5 percent developed ESKD over a median of 12 years [<a href="#rid37">37</a>]. However, there may be some bias in these studies since females who are initiated on ERT generally have more severe disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac outcomes </strong>– Observational studies in females receiving ERT have found that ERT can stabilize or improve left ventricular mass [<a href="#rid31">31,51,60,61,64</a>]. However, the impact of ERT on the risk of cardiovascular events (such as heart failure or myocardial infarction) remains uncertain. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic outcomes </strong>– Data are mixed regarding the effect of ERT on neuropathic pain, with some [<a href="#rid61">61,65</a>], but not all [<a href="#rid51">51</a>], studies showing that ERT decreases pain symptoms in females. The effects of ERT on the risk of stroke or TIA in females are unclear [<a href="#rid47">47</a>]. In one long-term observational study that followed 442 female patients on ERT for up to 3.2 years, the rate of stroke was 3 percent [<a href="#rid36">36</a>]. By comparison, prior to the institution of ERT, one study reported that 8 percent of females developed a stroke over a median of 12 years [<a href="#rid37">37</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal outcomes </strong>– ERT may improve gastrointestinal symptoms in some females with Fabry disease. In an analysis of 168 female patients enrolled in the Fabry Registry who were treated with <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> for a median of 5.7 years, the proportion of patients reporting abdominal pain decreased from 45 percent at baseline to 31 percent, and the proportion of patients reporting diarrhea decreased from 39 percent at baseline to 27 percent [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quality of life </strong>– Some [<a href="#rid55">55,60</a>], but not all [<a href="#rid51">51,56,57</a>], studies have shown that ERT may improve quality of life measures among females with Fabry disease.</p><p></p><p class="headingAnchor" id="H1349363735"><span class="h3">Patients with later-onset variants</span><span class="headingEndMark"> — </span>For males or females with later-onset variants who have symptoms or signs of major organ involvement (ie, kidney, cardiac, neurologic, gastrointestinal), we suggest Fabry-specific therapy plus supportive care, rather than supportive care alone. The choice of Fabry-specific therapy is discussed below. (See <a class="local">'Choice of therapy'</a> below.)</p><p></p><p>There are no randomized trials evaluating the efficacy of Fabry-specific therapy in patients with later-onset variants of Fabry disease. Available data are limited to mostly small observational studies evaluating the effects of ERT [<a href="#rid19">19,67-71</a>]. Collectively, these studies suggest that ERT may improve certain cardiac parameters and stabilize kidney function. It should be noted, however, that the majority of patients with later-onset variants will not develop ESKD if untreated [<a href="#rid72">72</a>]. The impact of ERT on survival and other important clinical endpoints such as ESKD and cardiovascular events is not known. In a study that included 37 males with later-onset disease, ERT with <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> or beta was associated with a reduction in left ventricular mass index [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H3782975516"><span class="h3">Patients with ESKD</span><span class="headingEndMark"> — </span>Some patients develop end-stage kidney disease (ESKD) and require dialysis or kidney transplantation before they are diagnosed with Fabry disease or before Fabry-specific therapy is initiated. Such patients may be considered for ERT on an individual basis, particularly if they experience quality-of-life issues such as neuropathic pain or bothersome gastrointestinal symptoms [<a href="#rid13">13,19</a>]. However, the potential benefits of ERT in this patient population are supported by very limited evidence, and initiating treatment with ERT should be weighed against the cost and burden of long-term therapy. <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">Migalastat</a> is contraindicated in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>.</p><p>Limited evidence suggests that patients with Fabry disease on dialysis may also benefit from treatment. These reported benefits are based on subjective improvement in self-reported symptoms such as heat intolerance, gastrointestinal symptoms, abdominal pain, pain medication usage, and acroparesthesias [<a href="#rid73">73,74</a>]. In addition, studies on the effects of ERT on neuropathic pain in patients on dialysis may be confounded by the presence of uremic polyneuropathy in these patients. (See  <a class="medical medical_review" href="/z/d/html/1837.html" rel="external">"Uremic polyneuropathy"</a>.)</p><p>Similarly, ERT may benefit patients with Fabry disease who have undergone kidney transplantation. One study found slower rates of GFR decline among transplant recipients treated with ERT compared with those not treated with ERT [<a href="#rid75">75</a>]. Other studies have observed a slower increase in left ventricular mass index in transplanted patients receiving ERT [<a href="#rid75">75,76</a>]. </p><p class="headingAnchor" id="H2764641378"><span class="h2">Choice of therapy</span><span class="headingEndMark"> — </span>Available Fabry-specific therapies include ERT (<a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a>, <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a>, or <a class="drug drug_general" data-topicid="141472" href="/z/d/drug information/141472.html" rel="external">pegunigalsidase alfa</a>) and pharmacologic chaperone therapy (<a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> hydrochloride). For patients who have an indication for Fabry-specific therapy, the choice between ERT and migalastat is influenced by factors such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgalafoldhcp.com%2Famenability&amp;token=fu2%2BO3uoSQSW8VnaP%2BBn72QlOCVth1Y1NL7%2BunVIqQa9gt%2FpBLyS%2BGZf1f3%2F4lbN&amp;TOPIC_ID=7207" target="_blank">amenability of the patient's GLA variant to migalastat</a>, patient age, baseline kidney function, and patient and clinician preference  (<a class="graphic graphic_algorithm graphicRef139011" href="/z/d/graphic/139011.html" rel="external">algorithm 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>Patients who do not have an amenable <em>GLA </em>gene variant, whose baseline eGFR is &lt;30 mL/min/1.73 m<sup>2</sup>, <strong>or</strong> who are &lt;18 years old (or &lt;12 years old if living in the European Union) should receive ERT (<a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> or beta). Those who are &gt;18 years old may be treated with <a class="drug drug_general" data-topicid="141472" href="/z/d/drug information/141472.html" rel="external">pegunigalsidase alfa</a>. The choice of ERT is frequently dictated by insurance coverage and cost. <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">Migalastat</a> should not be used in patients without an amenable <em>GLA </em>gene variant or with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>. Migalastat is not yet approved in the United States for individuals &lt;18 years old but is approved in the European Union for children ≥12 years old.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have an amenable <em>GLA </em>gene variant, whose baseline eGFR is ≥30 mL/min/1.73 m<sup>2</sup>, <strong>and </strong>who are ≥18 years old (or ≥12 years old if living in the European Union), both ERT and <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> are potential treatment options.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who are initiating Fabry-specific therapy for the first time, we engage in shared decision-making regarding the choice between ERT and <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a>. Patients who are already receiving treatment with ERT can be offered the option of switching to migalastat if desired. We inform patients that there is much more long-term clinical experience with ERT than with migalastat, and data directly comparing these two therapies are limited. Migalastat offers the convenience of oral dosing, compared with biweekly infusions with ERT, and is not impacted by antibody formation as may occur with ERT. In addition, migalastat is a small molecule that, unlike ERT, has a wide organ and cellular penetration and therefore may have the potential for a better metabolic correction [<a href="#rid77">77</a>]. However, treatment adherence with migalastat must be monitored. (See <a class="local">'Anti-agalsidase antibodies'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the patient is interested in <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> therapy, we first test the patient's alpha-Gal A leukocyte activity at baseline to confirm that the <em>GLA </em>gene variant is associated with deficient enzyme activity (ie, ≤35 percent of the mean normal). </p><p></p><p class="bulletIndent2">Once it has been confirmed that the patient has true enzyme deficiency, we assess if the patient's<em> GLA </em>gene variant is likely to result in a substantial increase in enzyme level (ie, increase in alpha-Gal A leukocyte activity close to or above the 35 percent disease threshold) with <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> therapy. This can be determined by reviewing a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5392595%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F9WyS2%2BmbISD1cPa9SCgRnci8vyKZ2%2Fmnf2fB28fHUVWWnHBGZXlaXx9XyymAHajYg%3D%3D&amp;TOPIC_ID=7207" target="_blank">published set</a> of known genetic variants that have been tested for their response to migalastat in vitro [<a href="#rid78">78</a>] or accessing an <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgalafoldhcp.com%2Famenability&amp;token=fu2%2BO3uoSQSW8VnaP%2BBn72QlOCVth1Y1NL7%2BunVIqQa9gt%2FpBLyS%2BGZf1f3%2F4lbN&amp;TOPIC_ID=7207" target="_blank">online website</a> that is updated with amenability data. Patients with a <em>GLA </em>gene variant that is likely to result in a substantial increase in enzyme level can be treated with migalastat instead of ERT. Patients with a <em>GLA </em>gene variant that is not likely to result in a substantial increase in enzyme level (eg, an increase from 1 to 6 percent of the mean normal) may not benefit from migalastat. In such patients, we treat with ERT. </p><p></p><p class="bulletIndent2">In vitro amenability testing does not always predict in vivo clinical responses in migalastat-treated patients [<a href="#rid79">79</a>]. Thus, in patients started on <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a>, clinical and biochemical evidence of amenability (ie, increased alpha-Gal A leukocyte activity and/or decreased plasma globotriaosylsphingosine [lysoGb3] levels) should be confirmed again after 4 to 12 weeks of therapy [<a href="#rid79">79</a>]. If there is no significant improvement in these parameters, the patient can be given the option of switching to ERT.  </p><p></p><p class="bulletIndent2">The efficacy and safety of ERT and <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> in patients with different clinical phenotypes are presented elsewhere in this topic. (See <a class="local">'Indications and timing of therapy'</a> above.)</p><p></p><p>There are few studies that have directly compared the efficacy of <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> and <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> with respect to clinical outcomes. In a multicenter retrospective study of 387 patients with Fabry disease (192 females; 248 on agalsidase alfa and 139 on agalsidase beta), rates of clinical events (defined as stage 5 chronic kidney disease [CKD], kidney transplantation or dialysis, implantation of an implantable cardiac defibrillator or pacemaker, stroke or TIA, or death) over a mean of 4.9 years were similar among patients receiving agalsidase alfa and those receiving agalsidase beta (26 and 27 percent, respectively) [<a href="#rid80">80</a>]. However, treatment with agalsidase beta was associated with a larger decrease in lysoGb3 concentrations compared with agalsidase alfa. Among patients with baseline left ventricular hypertrophy, a higher proportion had a decrease in left ventricular mass index after one year of treatment with agalsidase beta than with agalsidase alfa (79 versus 62 percent). <a class="drug drug_general" data-topicid="141472" href="/z/d/drug information/141472.html" rel="external">Pegunigalsidase alfa</a> has been shown to have similar rates of eGFR decline and plasma lyso-Gb3 concentrations as agalsidase beta [<a href="#rid10">10</a>].</p><p>Data directly comparing ERT with <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> are also limited. In one trial, 57 adults with Fabry disease who were previously treated with ERT (37 with <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a>, 19 with <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a>) were randomly assigned to receive 18 months of migalastat or continued treatment with ERT [<a href="#rid81">81</a>]. More than one-half (56 percent) of the patients were female, and most (88 percent) had multiorgan disease at baseline; the average duration of ERT prior to the start of the trial was approximately three years. Nearly two-thirds of the patients who received ERT before and during the trial received low-dose ERT (0.2 mg/kg every two weeks). At 18 months, migalastat and ERT had comparable effects on kidney function (mean annualized change in eGFR -0.40 versus -1.03 mL/min per 1.73 m<sup>2</sup>, respectively). Left ventricular mass index decreased from baseline in patients on migalastat but did not change significantly in those on ERT. There was no significant difference in the rate of kidney, cardiac, or cerebrovascular events or treatment-related adverse events between the two groups, but the power was limited to detect differences given the small sample size. Studies comparing migalastat with agalsidase beta at 1 mg/kg every 2 weeks are still needed.</p><p class="headingAnchor" id="H1441032059"><span class="h2">Enzyme replacement therapy</span><span class="headingEndMark"> — </span>ERT consists of providing affected patients with the deficient enzyme, alpha-Gal A. Three formulations of recombinant human alpha-Gal A are available: <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> (Replagal), <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> (Fabrazyme), and <a class="drug drug_general" data-topicid="141472" href="/z/d/drug information/141472.html" rel="external">pegunigalsidase alfa</a> (Elfabrio).</p><p class="headingAnchor" id="H2237819752"><span class="h3">Dosing and administration</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> –<strong> </strong>ERT doses are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">Agalsidase alfa</a> (Replagal) – 0.2 mg/kg or 0.4 mg/kg as an intravenous infusion every two weeks</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">Agalsidase beta</a> (Fabrazyme) – 1 mg/kg as an intravenous infusion every two weeks</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="141472" href="/z/d/drug information/141472.html" rel="external">Pegunigalsidase alfa</a> (Elfabrio) – 1 mg/kg as an intravenous infusion every two weeks</p><p></p><p class="bulletIndent1">Therapy should be continued at these doses indefinitely, if possible, for the following reasons:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gb3 clearance from tissues, once achieved, may not be maintained in patients who are switched to a lower dose. In one study, for example, standard-dose <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> for six months cleared Gb3 from the kidney endothelium and skin of 21 patients with Fabry disease [<a href="#rid82">82</a>]. Following a dose reduction (0.3 mg/kg every two weeks) that was administered for the subsequent 18 months, kidney endothelial and skin clearance was maintained in only 70 to 90 percent of patients, suggesting that the lower dose may not be adequate in all patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Due to a shortage of <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> in 2009, 67 of 105 stable patients receiving 1 mg/kg every two weeks either switched to <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> (38 patients) or had their agalsidase beta dose reduced to 0.3 to 0.5 mg/kg every two weeks (29 patients) [<a href="#rid83">83</a>]. After one year, both lower-dose ERT groups developed more frequent and more severe pain attacks. There was also a greater increase in albuminuria in the group switched to agalsidase alfa and a faster decline in kidney function in the group with reduced agalsidase beta dose, as compared with those who remained on higher doses of agalsidase beta.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– Given that infusion reactions may occur, ERT should be given slowly, and some, but not all, clinicians routinely administer pretreatment with antipyretics (<a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> 650 mg, 30 minutes prior to infusion). In the original ERT trials, <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> was given over 40 minutes [<a href="#rid29">29</a>], and <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> was ultimately given over a mean of 2 to 2.5 hours (approximately 10 percent of patients required a slower infusion) [<a href="#rid84">84</a>]. With agalsidase beta, the initial infusion rate should not exceed 15 mg/hour. If the patient tolerates the initial infusion, the infusion rate can be progressively increased by 3 to 5 mg/hour with each subsequent infusion until the minimum infusion time of 1.5 hours is reached or the patient develops an infusion reaction. Since infusion reactions only rarely occur in females, some experts choose to initiate ERT in females at a faster infusion rate. (See <a class="local">'Infusion reactions'</a> below.)</p><p></p><p class="bulletIndent1">With <a class="drug drug_general" data-topicid="141472" href="/z/d/drug information/141472.html" rel="external">pegunigalsidase alfa</a>, the recommended infusion rate for the initial four to six infusions is based on actual body weight depending on whether the patient is ERT-experienced or ERT-naïve [<a href="#rid85">85</a>]. If a patient tolerates the initial four to six infusions, the duration of every third infusion may be decreased in decrements of 30 minutes as tolerated. The minimum recommended infusion duration is 1.5 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Home therapy </strong>– ERT is initially administered in a clinical setting. However, home therapy with ERT is the preferred option for many patients who have uneventful infusions. Transitioning to home therapy is usually done after a minimum of four to six infusions, but timing may vary and may be dictated by insurance regulations.</p><p></p><p class="bulletIndent1">The safety and feasibility of long-term home infusions was examined in a study of 36 (17 males) carefully selected patients with Fabry disease in the Netherlands [<a href="#rid86">86</a>]. Patients were treated with either <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> or beta at a dose of 0.2 mg/kg, which they self-administered without medical supervision via a butterfly needle. Only six adverse events (chills or fever) occurred in six of these patients out of a total of over 1400 infusions, only three of which were at home. Hypotension or anaphylactoid events were not reported. Those who had a reaction were able to resume therapy with oral <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> premedication without further adverse events. This low rate of adverse events may be due to the fact that the dose of <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> in this study was substantially lower than in previous studies (0.2 versus 1 mg/kg). Another study of 79 patients (41 males) found that even patients with anti-agalsidase antibodies could be safely infused at home after 13 infusions in a center [<a href="#rid87">87</a>]. However, adverse events can occur in antibody-positive patients following increases in the speed of infusion; in such patients, the speed of infusion should be decreased. (See <a class="local">'Anti-agalsidase antibodies'</a> below.) </p><p></p><p class="headingAnchor" id="H3486566485"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Common side effects with ERT include infusion reactions and seroconversion (ie, the development of antibodies to either <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> or <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a>). Anaphylactic reactions are rare.</p><p></p><p class="headingAnchor" id="H3416492957"><span class="h4">Infusion reactions</span><span class="headingEndMark"> — </span>In the initial ERT trials, over 60 percent of participants (mainly males with the classic phenotype) developed rigors, fevers, or other infusion reactions, which tended to diminish over time and were readily controlled with premedication [<a href="#rid29">29,84</a>].</p><p>Infusion reactions were less frequent in some later studies of <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> and beta (reported to occur in &lt;20 percent), perhaps due to slower infusion rates and the use of pretreatment medications [<a href="#rid88">88,89</a>]. In these later studies, infusion reactions were generally mild and did not preclude resumption of treatment [<a href="#rid89">89</a>].</p><p>If the patient develops an infusion reaction, which is usually manifested by fever, tachycardia, rigors, hyper- or hypotension, and dyspnea, we proceed in the following way:</p><p class="bulletIndent1"><span class="glyph">●</span>Stop the infusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer intravenous (IV) <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, 0.5 to 1 mg/kg, not to exceed 50 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the reaction is severe, we also administer IV <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>, 1 to 2 mg/kg (not to exceed 100 mg), or IV <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 125 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the reaction resolves and the patient has normal vital signs, we restart the infusion at a slower rate (usually by 50 to 100 percent of the originally planned infusion duration; eg, 80 minutes for <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> and four hours for <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a>).</p><p></p><p>In patients who have had a mild infusion reaction, pretreatment with both oral <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> should be given prior to subsequent doses. In patients who have had moderate to severe infusion reactions, pretreatment with oral diphenhydramine (0.5 to 1 mg/kg, maximum dose 50 mg), <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">famotidine</a> (40 mg), and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (2 mg/kg or 50 to 60 mg) should be given the night before and two hours prior to therapy; alternatively, IV <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 125 mg can be given at the time of infusion. In addition, all patients with prior infusion reactions should receive ERT more slowly, with durations 50 to 100 percent longer than the duration in patients without infusion reactions.</p><p>If subsequent infusions are well tolerated, we continue the described pretreatment regimen for six months. Infusion reactions tend to diminish with longer duration of ERT. Thus, if no subsequent infusion reactions occur, we begin to slowly titrate off premedications. If no complications occur, we then begin to gradually shorten the duration of the infusion.</p><p>If infusion reactions continue despite these pretreatment regimens, other options include the addition of H1 antihistamines (eg, <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">loratadine</a>, <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a>) or, in severe cases that specifically involve dermatologic manifestations, <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a>. Tolerization protocols have also been used with some success in patients with Fabry disease [<a href="#rid90">90</a>]. </p><p>Although the foregoing approach describes our practice in most patients, highly individualized regimens may be required to prevent infusion reactions in some patients. However, once induced, antidrug antibodies are difficult to reduce. </p><p class="headingAnchor" id="H2359848960"><span class="h4">Anti-agalsidase antibodies</span><span class="headingEndMark"> — </span>Antibodies to recombinant <a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> and <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a> have been found to develop in 64 to 88 percent of patients receiving ERT in clinical trials [<a href="#rid29">29,84,91</a>]. In one open-label extension study, three patients were withdrawn for positive serum immunoglobulin E (IgE) or skin tests [<a href="#rid88">88</a>]. However, all later successfully resumed therapy, and none developed anaphylaxis.</p><p>Although earlier studies suggested that there was no correlation between the production of anti-agalsidase antibodies and clinical events [<a href="#rid92">92</a>], subsequent studies have found that the presence of such neutralizing antibodies may lower the efficacy of ERT [<a href="#rid93">93,94</a>]. As an example, an analysis of 168 patients with Fabry disease treated with ERT found that agalsidase inhibition (present in 40 percent) was associated with higher lysoGb3 levels, worse disease severity scores, greater left ventricular mass, and substantially lower GFR compared with no agalsidase inhibition [<a href="#rid93">93</a>]. In addition, agalsidase inhibition was associated with more Fabry disease symptoms, including worse diarrhea, fatigue, and neuropathic pain. Only higher ERT doses can compensate for these neutralizing antibodies [<a href="#rid94">94,95</a>]. However, increased immunosuppression was associated with lower antibody titers and reduced ERT inhibition in a group of male Fabry disease kidney and heart transplant recipients [<a href="#rid96">96</a>]. Further prospective studies are required to assess the long-term clinical impact of the seroconversion and to determine whether those with high antibody titers will require different dosing schedules. </p><p>An alloimmune form of membranous nephropathy (MN) has been documented in rare patients receiving ERT with recombinant human acid <a class="drug drug_general" data-topicid="9280" href="/z/d/drug information/9280.html" rel="external">alglucosidase alfa</a> for lysosomal acid alpha-glucosidase deficiency (Pompe disease) and with recombinant aryl-sulfatase B for mucopolysaccharidosis type VI. In both cases, the recombinant enzyme was detected and colocalized with immunoglobulin G (IgG) in the glomerular immune deposits. Although MN has not yet been reported in patients with Fabry disease receiving ERT, clinicians should be aware of the possibility of developing alloimmune MN due to an immunologic reaction to ERT in such patients. (See  <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Enzyme replacement therapy'</a>.)</p><p>Monitoring for anti-agalsidase antibodies is discussed below. (See <a class="local">'Monitoring'</a> below.)</p><p class="headingAnchor" id="H3801323122"><span class="h3">Discontinuation of ERT</span><span class="headingEndMark"> — </span>A consensus statement from the European Fabry Working Group has recommended that discontinuation of ERT be considered in patients with the following [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Noncompliance with &gt;50 percent of treatments</p><p class="bulletIndent1"><span class="glyph">●</span>Failure to regularly attend follow-up visits</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent life-threatening or severe infusion reactions that do not respond to prophylaxis (eg, anaphylaxis)</p><p class="bulletIndent1"><span class="glyph">●</span>ESKD, without an option for kidney transplantation, in combination with advanced heart failure (New York Heart Association class IV)</p><p class="bulletIndent1"><span class="glyph">●</span>End-stage Fabry disease or other comorbidities with a life expectancy of &lt;1 year</p><p class="bulletIndent1"><span class="glyph">●</span>Severe cognitive decline of any cause</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of treatment response for one year, when the primary indication for ERT is neuropathic pain while receiving maximum supportive care</p><p></p><p>The discontinuation of ERT was evaluated in a retrospective study of 75 patients with Fabry disease treated with ERT, of which 21 patients stopped treatment [<a href="#rid97">97</a>]. Compared with patients who remained on ERT, patients who stopped ERT were older at the initiation of treatment, more likely to have had cardiac complications or stroke prior to ERT, and more likely to have an eGFR of &lt;60 mL/min per 1.73 m<sup>2</sup>. The primary reasons for discontinuing ERT were patient request (eight patients), death or terminal illness (seven patients), and treatment failure (five patients). Although death occurred in 12 of the 21 patients, some patients remained stable at one year after treatment cessation.</p><p class="headingAnchor" id="H1789769054"><span class="h2">Chaperone therapy (migalastat)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">Migalastat</a> is an oral pharmacologic chaperone that binds to and stabilizes specific mutant forms of alpha-galactosidase, thereby facilitating proper trafficking of the enzyme to lysosomes and increasing enzyme activity. In preclinical studies, migalastat was shown to increase alpha-Gal A activity and decrease accumulation of Gb3 in cultured human Fabry disease cell lines and in animal models of Fabry disease [<a href="#rid12">12</a>]. Migalastat has been approved in the United States, Canada, and Europe for use as first-line therapy in adult Fabry patients with amenable <em>GLA</em> gene variants. It is approved in the European Union for children ages 12 and above. (See <a class="local">'Choice of therapy'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration </strong>– <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">Migalastat</a> is administered at a dose of 123 mg (equivalent to 150 mg of migalastat hydrochloride) orally once every other day. It should be taken without consuming food or caffeine two hours before and two hours after each dose to give a minimum four hour fast.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">Migalastat</a> is generally well tolerated among patients with Fabry disease [<a href="#rid98">98</a>]. The most commonly reported adverse effects include headache (25 to 35 percent), nasopharyngitis (18 to 33 percent), urinary tract infection (15 percent), nausea (12 percent), and pyrexia (12 percent) [<a href="#rid39">39,81</a>].</p><p></p><p class="headingAnchor" id="H1096374608"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>Other Fabry-specific therapies that are under investigation include moss-aGalactosidase A (NCT02995993) [<a href="#rid99">99</a>]; substrate reduction therapy such as venglustat and lucerastat [<a href="#rid100">100,101</a>]; and gene therapy [<a href="#rid102">102</a>].</p><p class="headingAnchor" id="H940104335"><span class="h1">SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>All patients with Fabry disease should receive supportive care as indicated to manage the kidney, cardiac, neurologic, and other complications of Fabry disease.</p><p class="headingAnchor" id="H624511323"><span class="h2">Kidney disease</span><span class="headingEndMark"> — </span>Patients with Fabry disease are at high risk for progressive kidney failure. Hypertensive patients and/or those with urine protein excretion &gt;500 mg/day should receive an inhibitor of the renin-angiotensin system (RAS), such as an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). Whether RAS blockade is beneficial for patients with Fabry disease who are normotensive or have urine protein excretion less than 500 mg/day is unclear. In addition, patients should receive standard care for complications of chronic kidney disease (CKD), and, when required, dialysis and/or transplantation. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H3961520352"><span class="h3">ACE inhibitors and ARBs</span><span class="headingEndMark"> — </span>Patients with Fabry disease who are hypertensive or who have proteinuria &gt;500 mg/day should receive an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) to lower the blood pressure and reduce proteinuria. This approach is similar to that for adult patients with CKD due to other causes who have hypertension and/or proteinuria. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Renin-angiotensin system inhibitors'</a>.)</p><p>Patients with Fabry disease who continue to have &gt;500 mg/day of proteinuria despite maximal doses of an ACE inhibitor or ARB or who have CKD may benefit from treatment with a sodium-glucose cotransporter 2 inhibitor although there are no data specifically in patients with Fabry disease. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Patients with proteinuria'</a>.)</p><p>Blood pressure goals in patients with Fabry disease and nephropathy are similar to those in patients with other forms of kidney disease. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p>Data are limited on the use of RAS inhibitors in addition to Fabry-specific therapy in patients with Fabry disease [<a href="#rid103">103-105</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A small series of 11 patients treated with RAS inhibitors suggested that these drugs are associated with a reduction in proteinuria and stabilization of the estimated glomerular filtration rate (eGFR) [<a href="#rid103">103</a>]. Similarly, another study found that patients achieving proteinuria reduction to or below 0.5 g/g creatinine with RAS inhibitors had slower rates of eGFR decline; however, these patients still had more than three times the expected rate of eGFR loss [<a href="#rid105">105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, a larger study compared the decline in eGFR and proteinuria in 84 patients treated with RAS inhibitors with 124 patients not treated with RAS inhibitors; all patients received enzyme replacement therapy (ERT) [<a href="#rid104">104</a>]. After more than five years, eGFR decline and proteinuria were nonsignificantly worse (not better) in patients treated with RAS inhibitors. Baseline information was not given about those treated and not treated with RAS inhibitors, and it is possible that RAS inhibitors appeared ineffective because the patients who received them had more advanced kidney disease at the start. On the other hand, ERT may mitigate the beneficial effects of RAS inhibitors by directly inhibiting the angiotensin-converting enzyme [<a href="#rid106">106</a>].</p><p></p><p class="headingAnchor" id="H991220422"><span class="h3">Dialysis</span><span class="headingEndMark"> — </span>Patients with Fabry disease who develop end-stage kidney disease (ESKD) may require maintenance dialysis. Both hemodialysis and peritoneal dialysis are potential modalities, and there is no evidence to support the use of one dialysis modality over the other.</p><p>In general, patients with Fabry disease fare worse with maintenance dialysis than other patients with ESKD. Overall survival is lower among patients with Fabry disease than in non-Fabry controls: </p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 42 patients who initiated dialysis between 1995 and 1997, 64 and 34 percent were treated with hemodialysis and peritoneal dialysis, respectively, with one patient being preemptively transplanted [<a href="#rid107">107</a>]. Three-year survival was slightly lower among these patients compared with control patients with nondiabetic ESKD (70 and 76 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a European Renal Association-European Dialysis and Transplant Association report that described patients initiating kidney replacement therapy between 1975 and 1993, five-year survival on dialysis was lower among patients with Fabry disease compared with the general dialysis population (41 versus 68 percent) [<a href="#rid108">108</a>].</p><p></p><p>Among patients with Fabry disease, the need to initiate kidney replacement therapy has been associated with a reduced quality of life [<a href="#rid109">109</a>]. Whether ERT affects the survival of patients with Fabry disease who are on dialysis is unknown. In addition, survival of patients with Fabry disease who are on dialysis as a bridge to transplantation is also unknown.</p><p class="headingAnchor" id="H1855994467"><span class="h3">Transplantation</span><span class="headingEndMark"> — </span>Patients with Fabry disease who develop ESKD are potential candidates for kidney transplantation. The evaluation of the potential kidney transplant recipient is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient"</a>.)</p><p>Graft and patient outcomes among transplant recipients with Fabry disease appear to be comparable with those of recipients who have ESKD due to other causes [<a href="#rid76">76,110-112</a>]. The following studies illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study that compared 93 transplant recipients with ESKD due to Fabry disease with a matched cohort of 186 recipients transplanted for ESKD due to other causes, five-year patient and graft survival were similar in patients with and without Fabry disease (83 and 75 percent versus 82 and 67 percent, respectively) [<a href="#rid111">111</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 17 kidney transplant recipients with Fabry disease who were followed for a median of 11.5 years (range, 0.8 to 25.5 years), graft survival was similar to that of matched controls without Fabry disease [<a href="#rid76">76</a>]. Patient survival among those with Fabry disease was 100 percent at 10 years, 67 percent at 15 years, and 25 percent at 20 years. Most deaths were attributed to cardiac events.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, one study that compared 197 kidney recipients with Fabry disease with a matched cohort of 1970 transplant recipients with other causes of ESKD found lower five-year patient survival among those with Fabry disease (81 versus 90 percent) [<a href="#rid112">112</a>]. Five-year graft survival was similar between the two groups. Cardiovascular complications were the leading cause of death in both Fabry and non-Fabry study populations. It should be noted that most patients in this study were followed during the pre-ERT era.</p><p></p><p>In general, clinically significant Fabry kidney disease does not recur in the transplanted kidney, although some recipients may develop endothelial cell globotriaosylceramide (Gb3) deposition that does not compromise graft function. As an example, the examination of kidney allograft tissue obtained six and eight months after transplantation has shown Fabry inclusions in vascular endothelial cells [<a href="#rid113">113</a>], possibly of recipient origin [<a href="#rid114">114,115</a>].</p><p class="headingAnchor" id="H3983472564"><span class="h2">Cardiovascular disease</span><span class="headingEndMark"> — </span>Patients with Fabry disease with cardiac manifestations should generally receive standard therapies for heart disease, including antianginal medication for angina, standard antiarrhythmic therapy (including preventive implantation of cardioverter-defibrillators in some patients with advanced cardiomyopathy), and guideline-directed therapy for heart failure. Heart transplantation is also feasible in patients with Fabry disease [<a href="#rid116">116</a>]. These issues are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4914.html" rel="external">"Fabry disease: Cardiovascular disease", section on 'Management'</a>.)</p><p class="headingAnchor" id="H670068833"><span class="h2">Neurologic disease</span><span class="headingEndMark"> — </span>Patients with chronic neuropathic pain may benefit from treatment with <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, or other anticonvulsants, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6194.html" rel="external">"Fabry disease: Neurologic manifestations", section on 'Pain relief'</a>.)</p><p>Patients with Fabry disease should receive standard measures for primary or secondary prevention of ischemic stroke, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6194.html" rel="external">"Fabry disease: Neurologic manifestations", section on 'Stroke prevention'</a>.) </p><p class="headingAnchor" id="H4292605325"><span class="h2">Other clinical manifestations</span><span class="headingEndMark"> — </span>Patients with Fabry disease may require treatment for other clinical manifestations, including gastrointestinal symptoms, lower extremity lymphedema, depression or anxiety, telangiectasias and angiokeratomas, erectile dysfunction, and hearing loss (see  <a class="medical medical_review" href="/z/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis", section on 'Clinical presentation'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal symptoms</strong> – Gastrointestinal symptoms, such as abdominal pain, recurrent nausea and vomiting, and either diarrhea or constipation, occur commonly among Fabry disease patients. We treat patients with such symptoms with an approach similar to that used in patients with irritable bowel syndrome who have functional gastrointestinal symptoms, as discussed elsewhere. In one case series, treatment with oral alpha-galactosidase as a dietary supplement (600 units three times daily) resulted in an improvement of gastrointestinal symptoms (mostly abdominal pain and diarrhea) [<a href="#rid117">117</a>]. (See  <a class="medical medical_review" href="/z/d/html/15930.html" rel="external">"Approach to functional gastrointestinal symptoms in adults with inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphedema</strong> – In patients with Fabry disease, it is important that peripheral lymphedema not be confused with fluid retention from kidney or cardiac causes as this could lead to inappropriate fluid and salt restriction and diuresis. The management of peripheral lymphedema is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/17013.html" rel="external">"Lower extremity lymphedema", section on 'Conservative care'</a> and  <a class="medical medical_review" href="/z/d/html/738.html" rel="external">"Clinical staging and conservative management of peripheral lymphedema", section on 'Overview of management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Depression and anxiety</strong> – Depression and anxiety are common in Fabry disease, often overlooked, and consequently often left untreated despite their substantial contribution to decreased quality of life. The diagnosis and treatment of depression are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatologic manifestations</strong> – Dermatologic manifestations of Fabry disease (telangiectasias and angiokeratomas) are generally treated in collaboration with a dermatologist. Cosmetic treatment of these skin manifestations and sometimes bleeding complications frequently involves laser therapy, as discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13638.html" rel="external">"Laser and light therapy for cutaneous vascular lesions"</a> and  <a class="medical medical_review" href="/z/d/html/8176.html" rel="external">"Laser and light therapy of lower extremity telangiectasias, reticular veins, and small varicose veins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erectile dysfunction</strong> – The treatment of erectile dysfunction is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">"Treatment of male sexual dysfunction", section on 'Erectile dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hearing loss and vertigo</strong> – The treatment of hearing loss and vertigo in Fabry disease patients is similar to that in non-Fabry disease patients and is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6849.html" rel="external">"Hearing amplification in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5097.html" rel="external">"Treatment of vertigo"</a>.)</p><p></p><p class="bulletIndent1">Sudden deafness can occur in male and female patients with classic Fabry disease [<a href="#rid118">118,119</a>] and should be treated as for patients with idiopathic sudden sensorineural hearing loss. (See  <a class="medical medical_review" href="/z/d/html/6847.html" rel="external">"Sudden sensorineural hearing loss in adults: Evaluation and management"</a>.)</p><p></p><p class="headingAnchor" id="H2570073518"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>All patients with Fabry disease should have continued monitoring regardless of whether or not they are receiving therapy [<a href="#rid2">2</a>]. The extent and timing of evaluations should take into consideration a patient's disease manifestations, disease severity, and side effects of therapy. </p><p></p><p>In all patients who are treated with Fabry-specific therapy, clinical monitoring is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>We perform a clinical evaluation and obtain routine blood chemistries (including serum creatinine concentration) and a complete blood count every 6 to 12 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We obtain an estimation of the glomerular filtration rate (eGFR) and a urine protein-to-creatinine ratio every three to six months. We use serial measurements of eGFR over time to calculate an eGFR slope and determine the patient's rate of annual kidney function decline; the goal of therapy is to limit the eGFR decline to the normal age-related decline of glomerular filtration rate (GFR). (See <a class="local">'Goals of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with cardiac involvement, we obtain an electrocardiogram every 6 to 12 months. In addition, we obtain an echocardiogram (including measurement of global longitudinal strain) once yearly and/or cardiac magnetic resonance imaging once every three to five years using a Fabry disease-specific protocol [<a href="#rid2">2</a>]. A 48-hour Holter recorder or an event recorder may be considered to detect possible arrhythmias.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients receiving enzyme replacement therapy (ERT), we routinely test for anti-agalsidase antibodies prior to initiation of ERT, then at six months after ERT initiation, and yearly thereafter. Testing for anti-agalsidase antibodies is not required in patients treated with <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a>. (See <a class="local">'Anti-agalsidase antibodies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We measure plasma globotriaosylsphingosine (lysoGb3) levels at least once yearly in patients receiving ERT or <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> [<a href="#rid120">120</a>]. One study suggested that an increase in plasma lysoGb3 levels while a patient is receiving ERT may indicate the development of anti-agalsidase antibodies, but these findings require further validation in larger studies [<a href="#rid93">93</a>]. </p><p></p><p>Clinical monitoring of patients with Fabry disease who are not receiving Fabry-specific therapy is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis", section on 'Follow-up assessment'</a>.)</p><p class="headingAnchor" id="H2489589348"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Survival is substantially reduced in untreated males with classic Fabry disease [<a href="#rid3">3</a>]. Median cumulative survival is approximately 50 years, with very few individuals alive after the age of 60 years [<a href="#rid38">38,121</a>]. Most deaths are due to cardiovascular disease (including stroke, myocardial infarction, and heart failure) although deaths from kidney failure, sepsis, and suicide have also been reported [<a href="#rid38">38,121</a>]. Whether Fabry-specific therapy (enzyme replacement therapy [ERT] or <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a>) impacts survival remains unclear.</p><p>Data on other long-term clinical outcomes are provided by studies of the natural history of Fabry disease in patients prior to ERT:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 447 patients (279 males, 168 females) followed for a median of 12 years, end-stage kidney disease (ESKD) developed in 18 percent of males and 5 percent of females at a median age of 39 and 42 years, respectively [<a href="#rid37">37</a>]. Myocardial infarction occurred in 3 percent of males and 2 percent of females, and heart failure developed in 4 percent of males and 1 percent of females. Stroke occurred in 11 percent of males and 8 percent of females. The mean age for first stroke was 42 and 45 years, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of the natural history of 2869 patients (1424 males, 1445 females) in the Fabry Registry prior to the institution of ERT, 6 percent of males and 4 percent of females experienced major cardiovascular events (myocardial infarction, heart failure, or cardiac-related death) [<a href="#rid122">122</a>]. Among those with a cardiovascular event, 30 percent of males and 6 percent of females also experienced a kidney event (kidney transplant or chronic dialysis), and 11 percent of males and 13 percent of females also experienced stroke.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 499 adult patients before ERT treatment, males with classical Fabry disease had a higher risk of clinical events (kidney, cardiac, or cerebral) than males with nonclassical disease or females with either phenotype [<a href="#rid72">72</a>]. Females with classical Fabry disease were also more likely to develop complications than those with nonclassical disease.</p><p></p><p class="headingAnchor" id="H2723470476"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122565.html" rel="external">"Society guideline links: Fabry disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H3038000778"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy </strong>– The overall goals of therapy in patients with Fabry disease are to prevent progression to irreversible tissue damage, organ failure, and premature death, and to improve quality of life. Treatment generally consists of Fabry-specific therapy (such as enzyme replacement therapy [ERT] or chaperone therapy [<a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a>]) for those with indications, as well as adjunctive therapies for Fabry disease complications. Since disease manifestations vary among individual patients, therapeutic goals should be individualized based upon the extent of organ involvement. (See <a class="local">'Goals of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fabry-specific therapy </strong>– Available Fabry-specific therapies include ERT and chaperone therapy (ie, <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a>). ERT consists of providing affected patients with the deficient enzyme, alpha-galactosidase A (alpha-Gal A). Migalastat is an oral pharmacologic chaperone that binds to and stabilizes specific mutant forms of alpha-Gal A, thereby facilitating proper trafficking of the enzyme to lysosomes and increasing enzyme activity. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications </strong>– For the following patients with Fabry disease, we suggest Fabry-specific therapy plus supportive care, rather than supportive care alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>All males with classic Fabry disease. (See <a class="local">'Males with classic Fabry disease'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Female heterozygotes who have clinical symptoms or signs of major organ involvement (ie, kidney, cardiac, neurologic, gastrointestinal) or asymptomatic female heterozygotes with laboratory, histologic, functional, or radiologic evidence of major organ injury. (See <a class="local">'Female heterozygotes'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Males or females with later-onset variants who have clinical symptoms or signs of major organ involvement (ie, kidney, cardiac, neurologic, gastrointestinal). (See <a class="local">'Patients with later-onset variants'</a> above.)</p><p></p><p class="bulletIndent2">Patients with end-stage kidney disease (ESKD) due to Fabry disease may be considered for ERT on an individual basis. (See <a class="local">'Patients with ESKD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of therapy </strong>– The choice between ERT and <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> is influenced by factors such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgalafoldhcp.com%2Famenability&amp;token=fu2%2BO3uoSQSW8VnaP%2BBn72QlOCVth1Y1NL7%2BunVIqQa9gt%2FpBLyS%2BGZf1f3%2F4lbN&amp;TOPIC_ID=7207" target="_blank">amenability of the patient's GLA variant to migalastat</a>, patient age, baseline kidney function, and patient and clinician preference  (<a class="graphic graphic_algorithm graphicRef139011" href="/z/d/graphic/139011.html" rel="external">algorithm 1</a>) (see <a class="local">'Choice of therapy'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients who do not have an amenable <em>GLA </em>gene<em> </em>variant, whose baseline estimated glomerular filtration rate (eGFR) is &lt;30 mL/min/1.73 m<sup>2</sup>, <strong>or</strong> who are &lt;18 years old (or &lt;12 years old if living in the European Union) should receive ERT (<a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> or beta or <a class="drug drug_general" data-topicid="141472" href="/z/d/drug information/141472.html" rel="external">pegunigalsidase alfa</a>). Agalsidase alfa is not approved for use in the United States. <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">Migalastat</a> should not be used in patients without an amenable <em>GLA </em>gene variant or with an eGFR is &lt;30 mL/min/1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients who have an amenable <em>GLA </em>gene variant, whose baseline eGFR is ≥30 mL/min/1.73 m<sup>2</sup>, <strong>and</strong> who are ≥18 years old (or ≥12 years old if living in the European Union), both ERT and <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> are potential options. We engage in shared decision-making regarding the choice between ERT and migalastat.</p><p></p><p class="bulletIndent2">Dosing, administration, and adverse effects of ERT and <a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a> are discussed above. (See <a class="local">'Enzyme replacement therapy'</a> above and <a class="local">'Chaperone therapy (migalastat)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care </strong>– All patients with Fabry disease should receive supportive care as indicated to manage the kidney, cardiac, neurologic, and other complications of disease. (See <a class="local">'Kidney disease'</a> above and <a class="local">'Cardiovascular disease'</a> above and <a class="local">'Neurologic disease'</a> above and <a class="local">'Other clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring </strong>– All patients with Fabry disease should have continued monitoring whether or not they are receiving therapy. The extent and timing of evaluations should take into consideration a patient’s disease manifestations, disease severity, and side effects of therapy. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Jeffrey B Kopp, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wanner C, Arad M, Baron R, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab 2018; 124:189.</a></li><li><a class="nounderline abstract_t">Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 2018; 123:416.</a></li><li><a class="nounderline abstract_t">Waldek S, Patel MR, Banikazemi M, et al. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 2009; 11:790.</a></li><li><a class="nounderline abstract_t">Baig S, Edward NC, Kotecha D, et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace 2018; 20:f153.</a></li><li><a class="nounderline abstract_t">Pieroni M, Moon JC, Arbustini E, et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2021; 77:922.</a></li><li><a class="nounderline abstract_t">Kolodny E, Fellgiebel A, Hilz MJ, et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke 2015; 46:302.</a></li><li><a class="nounderline abstract_t">Lidove O, Zeller V, Chicheportiche V, et al. Musculoskeletal manifestations of Fabry disease: A retrospective study. Joint Bone Spine 2016; 83:421.</a></li><li><a class="nounderline abstract_t">Politei J. Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued. Mol Genet Metab 2020; 130:227.</a></li><li><a class="nounderline abstract_t">Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial. J Inherit Metab Dis 2019; 42:534.</a></li><li><a class="nounderline abstract_t">Wallace E, Goker-Alpan W, Holida B, et al. First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study. Mol Genet Metab 2023; 138:107351.</a></li><li><a class="nounderline abstract_t">El Dib R, Gomaa H, Carvalho RP, et al. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2016; 7:CD006663.</a></li><li><a class="nounderline abstract_t">Germain DP, Fan JQ. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies. Int J Clin Pharmacol Ther 2009; 47 Suppl 1:S111.</a></li><li><a class="nounderline abstract_t">Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017; 91:284.</a></li><li><a class="nounderline abstract_t">Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 2015; 10:36.</a></li><li><a class="nounderline abstract_t">Hopkin RJ, Jefferies JL, Laney DA, et al. The management and treatment of children with Fabry disease: A United States-based perspective. Mol Genet Metab 2016; 117:104.</a></li><li><a class="nounderline abstract_t">Terryn W, Cochat P, Froissart R, et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant 2013; 28:505.</a></li><li><a class="nounderline abstract_t">Germain DP, Fouilhoux A, Decramer S, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet 2019; 96:107.</a></li><li><a class="nounderline abstract_t">Linhart A, Germain DP, Olivotto I, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail 2020; 22:1076.</a></li><li><a class="nounderline abstract_t">Germain DP, Elliott PM, Falissard B, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep 2019; 19:100454.</a></li><li><a class="nounderline abstract_t">Spada M, Baron R, Elliott PM, et al. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts. Mol Genet Metab 2019; 126:212.</a></li><li><a class="nounderline abstract_t">Ortiz A, Abiose A, Bichet DG, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet 2016; 53:495.</a></li><li><a class="nounderline abstract_t">El Dib R, Gomaa H, Ortiz A, et al. Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS One 2017; 12:e0173358.</a></li><li><a class="nounderline abstract_t">Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 2015; 52:353.</a></li><li><a class="nounderline abstract_t">Tøndel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 2013; 24:137.</a></li><li><a class="nounderline abstract_t">Skrunes R, Tøndel C, Leh S, et al. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease. Clin J Am Soc Nephrol 2017; 12:1470.</a></li><li><a class="nounderline abstract_t">Warnock DG, Ortiz A, Mauer M, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 2012; 27:1042.</a></li><li><a class="nounderline abstract_t">Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment. Orphanet J Rare Dis 2015; 10:125.</a></li><li><a class="nounderline abstract_t">Weidemann F, Niemann M, Störk S, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 2013; 274:331.</a></li><li><a class="nounderline abstract_t">Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285:2743.</a></li><li><a class="nounderline abstract_t">Schiffmann R, Ries M, Timmons M, et al. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006; 21:345.</a></li><li><a class="nounderline abstract_t">Kim JH, Lee BH, Hyang Cho J, et al. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes. J Hum Genet 2016; 61:923.</a></li><li><a class="nounderline abstract_t">Beck M, Hughes D, Kampmann C, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. Mol Genet Metab Rep 2015; 3:21.</a></li><li><a class="nounderline abstract_t">van der Veen SJ, Körver S, Hirsch A, et al. Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression. Mol Genet Metab 2022; 135:163.</a></li><li><a class="nounderline abstract_t">Ramaswami U, Beck M, Hughes D, et al. Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis. Drug Des Devel Ther 2019; 13:3705.</a></li><li><a class="nounderline abstract_t">West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009; 20:1132.</a></li><li><a class="nounderline abstract_t">Hopkin RJ, Cabrera G, Charrow J, et al. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Mol Genet Metab 2016; 119:151.</a></li><li><a class="nounderline abstract_t">Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24:2102.</a></li><li><a class="nounderline abstract_t">Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81:122.</a></li><li><a class="nounderline abstract_t">Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med 2016; 375:545.</a></li><li><a class="nounderline abstract_t">Mauer M, Sokolovskiy A, Barth JA, et al. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment. J Med Genet 2017; 54:781.</a></li><li><a class="nounderline abstract_t">Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab 2020; 131:219.</a></li><li><a class="nounderline abstract_t">Bichet DG, Torra R, Wallace E, et al. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease. Mol Genet Metab Rep 2021; 28:100786.</a></li><li><a class="nounderline abstract_t">Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008; 94:153.</a></li><li><a class="nounderline abstract_t">Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009; 119:524.</a></li><li><a class="nounderline abstract_t">Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006; 97:1515.</a></li><li><a class="nounderline abstract_t">Schuller Y, Linthorst GE, Hollak CE, et al. Pain management strategies for neuropathic pain in Fabry disease--a systematic review. BMC Neurol 2016; 16:25.</a></li><li><a class="nounderline abstract_t">Körver S, Longo MGF, Lima MR, et al. Determinants of cerebral radiological progression in Fabry disease. J Neurol Neurosurg Psychiatry 2020; 91:756.</a></li><li><a class="nounderline abstract_t">Hoffmann B, Schwarz M, Mehta A, et al. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007; 5:1447.</a></li><li><a class="nounderline abstract_t">Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 2005; 85:255.</a></li><li><a class="nounderline abstract_t">Dehout F, Roland D, Treille de Granseigne S, et al. Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease. J Inherit Metab Dis 2004; 27:499.</a></li><li><a class="nounderline abstract_t">Hughes DA, Barba Romero MÁ, Hollak CE, et al. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey. Mol Genet Metab 2011; 103:207.</a></li><li><a class="nounderline abstract_t">Hopkin RJ, Feldt-Rasmussen U, Germain DP, et al. Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype. Mol Genet Metab Rep 2020; 25:100670.</a></li><li><a class="nounderline abstract_t">Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68:711.</a></li><li><a class="nounderline abstract_t">Eto Y, Ohashi T, Utsunomiya Y, et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis 2005; 28:575.</a></li><li><a class="nounderline abstract_t">Watt T, Burlina AP, Cazzorla C, et al. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med 2010; 12:703.</a></li><li><a class="nounderline abstract_t">Smid BE, Rombach SM, Aerts JM, et al. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 2011; 6:69.</a></li><li><a class="nounderline abstract_t">Ghali J, Nicholls K, Denaro C, et al. Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience. JIMD Rep 2012; 3:33.</a></li><li><a class="nounderline abstract_t">Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet 2016; 89:44.</a></li><li><a class="nounderline abstract_t">Germain DP, Arad M, Burlina A, et al. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts. Mol Genet Metab 2019; 126:224.</a></li><li><a class="nounderline abstract_t">Baehner F, Kampmann C, Whybra C, et al. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 2003; 26:617.</a></li><li><a class="nounderline abstract_t">Whybra C, Miebach E, Mengel E, et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 2009; 11:441.</a></li><li><a class="nounderline abstract_t">Feriozzi S, Schwarting A, Sunder-Plassmann G, et al. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 2009; 29:353.</a></li><li><a class="nounderline abstract_t">Moreno-Martinez D, Aguiar P, Auray-Blais C, et al. Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. Mol Genet Metab 2021; 132:234.</a></li><li><a class="nounderline abstract_t">Motwani M, Banypersad S, Woolfson P, Waldek S. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab 2012; 107:197.</a></li><li><a class="nounderline abstract_t">Hoffmann B, Beck M, Sunder-Plassmann G, et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007; 23:535.</a></li><li><a class="nounderline abstract_t">Wilcox WR, Feldt-Rasmussen U, Martins AM, et al. Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. JIMD Rep 2018; 38:45.</a></li><li><a class="nounderline abstract_t">Lin HY, Liu HC, Huang YH, et al. Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G&gt;A). BMJ Open 2013; 3.</a></li><li><a class="nounderline abstract_t">Liu HC, Lin HY, Yang CF, et al. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G&gt;A). Orphanet J Rare Dis 2014; 9:111.</a></li><li><a class="nounderline abstract_t">Komori M, Sakurai Y, Kojima H, et al. Long-term effect of enzyme replacement therapy with fabry disease. Int J Otolaryngol 2013; 2013:282487.</a></li><li><a class="nounderline abstract_t">Anderson LJ, Wyatt KM, Henley W, et al. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014; 37:969.</a></li><li><a class="nounderline abstract_t">Suntjens EB, Smid BE, Biegstraaten M, et al. Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy. J Inherit Metab Dis 2015; 38:351.</a></li><li><a class="nounderline abstract_t">Arends M, Wanner C, Hughes D, et al. Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. J Am Soc Nephrol 2017; 28:1631.</a></li><li><a class="nounderline abstract_t">Pastores GM, Boyd E, Crandall K, et al. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 2007; 22:1920.</a></li><li><a class="nounderline abstract_t">Pisani A, Spinelli L, Sabbatini M, et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 2005; 46:120.</a></li><li><a class="nounderline abstract_t">Mignani R, Feriozzi S, Pisani A, et al. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 2008; 23:1628.</a></li><li><a class="nounderline abstract_t">Ersözlü S, Desnick RJ, Huynh-Do U, et al. Long-term Outcomes of Kidney Transplantation in Fabry Disease. Transplantation 2018; 102:1924.</a></li><li><a class="nounderline abstract_t">Wu YS, Khanna R, Schmith V, et al. Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice. Clin Pharmacol Drug Dev 2021; 10:1075.</a></li><li><a class="nounderline abstract_t">Benjamin ER, Della Valle MC, Wu X, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med 2017; 19:430.</a></li><li><a class="nounderline abstract_t">Lenders M, Stappers F, Brand E. In Vitro and In Vivo Amenability to Migalastat in Fabry Disease. Mol Ther Methods Clin Dev 2020; 19:24.</a></li><li><a class="nounderline abstract_t">Arends M, Biegstraaten M, Wanner C, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet 2018; 55:351.</a></li><li><a class="nounderline abstract_t">Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 2017; 54:288.</a></li><li><a class="nounderline abstract_t">Lubanda JC, Anijalg E, Bzdúch V, et al. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 2009; 11:256.</a></li><li><a class="nounderline abstract_t">Weidemann F, Krämer J, Duning T, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol 2014; 25:837.</a></li><li><a class="nounderline abstract_t">Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345:9.</a></li><li class="breakAll">ELFABRIO (pegunigalsidase alfa-iwxj) injection. United States prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761161s000lbl.pdf (Accessed on June 06, 2023).</li><li><a class="nounderline abstract_t">Linthorst GE, Vedder AC, Ormel EE, et al. Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands. Nephrol Dial Transplant 2006; 21:355.</a></li><li><a class="nounderline abstract_t">Smid BE, Hoogendijk SL, Wijburg FA, et al. A revised home treatment algorithm for Fabry disease: influence of antibody formation. Mol Genet Metab 2013; 108:132.</a></li><li><a class="nounderline abstract_t">Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75:65.</a></li><li><a class="nounderline abstract_t">Beck M, Ricci R, Widmer U, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004; 34:838.</a></li><li><a class="nounderline abstract_t">van der Veen SJ, Vlietstra WJ, van Dussen L, et al. Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease. Int J Mol Sci 2020; 21.</a></li><li><a class="nounderline abstract_t">Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146:77.</a></li><li><a class="nounderline abstract_t">Bénichou B, Goyal S, Sung C, et al. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 2009; 96:4.</a></li><li><a class="nounderline abstract_t">Lenders M, Stypmann J, Duning T, et al. Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease. J Am Soc Nephrol 2016; 27:256.</a></li><li><a class="nounderline abstract_t">Lenders M, Neußer LP, Rudnicki M, et al. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease. J Am Soc Nephrol 2018; 29:2879.</a></li><li><a class="nounderline abstract_t">Lenders M, Schmitz B, Brand SM, et al. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion. J Allergy Clin Immunol 2018; 141:2289.</a></li><li><a class="nounderline abstract_t">Lenders M, Oder D, Nowak A, et al. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med 2017; 282:241.</a></li><li><a class="nounderline abstract_t">Arends M, Linthorst GE, Hollak CE, Biegstraaten M. Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort. Mol Genet Metab 2016; 117:194.</a></li><li><a class="nounderline abstract_t">McCafferty EH, Scott LJ. Migalastat: A Review in Fabry Disease. Drugs 2019; 79:543.</a></li><li><a class="nounderline abstract_t">Hennermann JB, Arash-Kaps L, Fekete G, et al. Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease. J Inherit Metab Dis 2019; 42:527.</a></li><li><a class="nounderline abstract_t">Ashe KM, Budman E, Bangari DS, et al. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease. Mol Med 2015; 21:389.</a></li><li><a class="nounderline abstract_t">Guérard N, Morand O, Dingemanse J. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J Rare Dis 2017; 12:9.</a></li><li><a class="nounderline abstract_t">Khan A, Barber DL, Huang J, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun 2021; 12:1178.</a></li><li><a class="nounderline abstract_t">Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007; 18:2609.</a></li><li><a class="nounderline abstract_t">Feriozzi S, Torras J, Cybulla M, et al. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol 2012; 7:60.</a></li><li><a class="nounderline abstract_t">Warnock DG, Thomas CP, Vujkovac B, et al. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet 2015; 52:860.</a></li><li><a class="nounderline abstract_t">Batista EC, Carvalho LR, Casarini DE, et al. ACE activity is modulated by the enzyme α-galactosidase A. J Mol Med (Berl) 2011; 89:65.</a></li><li><a class="nounderline abstract_t">Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61:249.</a></li><li><a class="nounderline abstract_t">Tsakiris D, Simpson HK, Jones EH, et al. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996; 11 Suppl 7:4.</a></li><li><a class="nounderline abstract_t">Wagner M, Krämer J, Blohm E, et al. Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease. BMC Nephrol 2014; 15:188.</a></li><li><a class="nounderline abstract_t">Maizel SE, Simmons RL, Kjellstrand C, Fryd DS. Ten-year experience in renal transplantation for Fabry's disease. Transplant Proc 1981; 13:57.</a></li><li><a class="nounderline abstract_t">Ojo A, Meier-Kriesche HU, Friedman G, et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 2000; 69:2337.</a></li><li><a class="nounderline abstract_t">Shah T, Gill J, Malhotra N, et al. Kidney transplant outcomes in patients with Fabry disease. Transplantation 2009; 87:280.</a></li><li><a class="nounderline abstract_t">Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002; 13 Suppl 2:S134.</a></li><li><a class="nounderline abstract_t">Peces R. Is there true recurrence of Fabry's disease in the transplanted kidney? Nephrol Dial Transplant 1996; 11:561.</a></li><li><a class="nounderline abstract_t">Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ, et al. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 2001; 357:33.</a></li><li><a class="nounderline abstract_t">Di Nora C, Livi U. Heart transplantation in cardiac storage diseases: data on Fabry disease and cardiac amyloidosis. Curr Opin Organ Transplant 2020; 25:211.</a></li><li><a class="nounderline abstract_t">Lenders M, Boutin M, Auray-Blais C, Brand E. Effects of Orally Delivered Alpha-Galactosidase A on Gastrointestinal Symptoms in Patients With Fabry Disease. Gastroenterology 2020; 159:1602.</a></li><li><a class="nounderline abstract_t">Köping M, Shehata-Dieler W, Schneider D, et al. Characterization of vertigo and hearing loss in patients with Fabry disease. Orphanet J Rare Dis 2018; 13:137.</a></li><li><a class="nounderline abstract_t">Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002; 3:10.</a></li><li><a class="nounderline abstract_t">Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin Exp Nephrol 2018; 22:843.</a></li><li><a class="nounderline abstract_t">MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38:750.</a></li><li><a class="nounderline abstract_t">Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J Am Coll Cardiol 2011; 57:1093.</a></li></ol></div><div id="topicVersionRevision">Topic 7207 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30017653" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : European expert consensus statement on therapeutic goals in Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29530533" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Fabry disease revisited: Management and treatment recommendations for adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19745746" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29045633" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33602475" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25492902" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cerebrovascular involvement in Fabry disease: current status of knowledge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26697993" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Musculoskeletal manifestations of Fabry disease: A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32561366" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30834538" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27454104" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Enzyme replacement therapy for Anderson-Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20040321" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27998644" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25885911" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26546059" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The management and treatment of children with Fabry disease: A United States-based perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23234755" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30941742" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32640076" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : An expert consensus document on the management of cardiovascular manifestations of Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30775256" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29785937" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26993266" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Time to treatment benefit for adult patients with Fabry disease receiving agalsidaseβ: data from the Fabry Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28296917" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795794" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23274955" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Agalsidase benefits renal histology in young patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28625968" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21804088" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26416388" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23586858" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11386930" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Enzyme replacement therapy in Fabry disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204287" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27334365" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26937390" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35033446" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31749608" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357250" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Agalsidase alfa and kidney dysfunction in Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27510433" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19218538" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889412" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27509102" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28756410" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33012654" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34401344" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term follow-up of renal function in patients treated with migalastat for Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17483124" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153271" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16679096" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26911544" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pain management strategies for neuropathic pain in Fabry disease--a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32317398" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Determinants of cerebral radiological progression in Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919989" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939645" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15303007" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21543245" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33163363" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11179018" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902561" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20885332" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22041095" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23430871" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25974833" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : X-chromosome inactivation in female patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30413388" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14707510" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19346951" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18974635" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Agalsidase alfa slows the decline in renal function in patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33642210" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704481" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Enzyme replacement therapy improves cardiac features and severity of Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575495" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28510034" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23864212" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G&gt;A).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25047006" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G&gt;A).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24223040" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term effect of enzyme replacement therapy with fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24831586" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25395255" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27979989" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17395657" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983965" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057066" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29688992" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term Outcomes of Kidney Transplantation in Fabry Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33876577" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27657681" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32995357" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : In Vitro and In Vivo Amenability to Migalastat in Fabry Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437868" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27834756" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265719" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24556354" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11439963" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11439963" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249196" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23332169" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A revised home treatment algorithm for Fabry disease: influence of antibody formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15154115" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606727" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Fabry disease: overall effects of agalsidase alfa treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32806627" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17179052" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19022694" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25933799" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30385651" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29421273" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28682471" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26654842" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30875019" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Migalastat: A Review in Fabry Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30746723" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25938659" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28088251" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33633114" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Lentivirus-mediated gene therapy for Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17656478" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22246281" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26490103" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20941593" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : ACE activity is modulated by the enzymeα-galactosidase A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786107" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Patients with Fabry disease on dialysis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9067983" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25432518" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6791331" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Ten-year experience in renal transplantation for Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10868636" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Excellent outcome of renal transplantation in patients with Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155985" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Kidney transplant outcomes in patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12068025" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Renal pathology in Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8671839" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Is there true recurrence of Fabry's disease in the transplanted kidney?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11197359" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Endothelial cell chimerism after renal transplantation and vascular rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32304420" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Heart transplantation in cardiac storage diseases: data on Fabry disease and cardiac amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32534932" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effects of Orally Delivered Alpha-Galactosidase A on Gastrointestinal Symptoms in Patients With Fabry Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30111353" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Characterization of vertigo and hearing loss in patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12377100" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29288396" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11694547" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349401" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Cardiovascular events in patients with fabry disease natural history data from the fabry registry.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
